
Akouos AKUS
Quartalsbericht 2022-Q3
hinzugefügt 14.11.2022
Akouos Anteile 2011-2026 | AKUS
Anteile Jährlich Akouos
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 34.4 M | 34.2 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 34.4 M | 34.2 M | 34.3 M |
Anteile Vierteljährlich Akouos
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 36.9 M | 35.8 M | 34.5 M | 34.5 M | 34.4 M | 34.4 M | 34.3 M | 34.4 M | 15.3 M | 1.12 M | 708 K | 997 K | 622 K | 587 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 36.9 M | 587 K | 21.3 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Mesoblast Limited
MESO
|
649 M | $ 14.32 | 2.14 % | $ 9.29 B | ||
|
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
187 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
17.9 M | - | 10.36 % | $ 9.8 M | ||
|
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
54.8 M | $ 215.54 | -1.16 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 19.23 | - | $ 899 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
13.3 M | $ 8.18 | -2.97 % | $ 109 M | ||
|
MediciNova
MNOV
|
49.1 M | $ 1.45 | - | $ 71.1 M | ||
|
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
11.5 M | $ 0.71 | 17.15 % | $ 8.13 M | ||
|
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | ||
|
Exelixis
EXEL
|
272 M | $ 41.57 | 0.39 % | $ 11.3 B | ||
|
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.32 | -5.71 % | $ 337 M | ||
|
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
69.9 K | - | - | $ 3.74 B | ||
|
Genmab A/S
GMAB
|
630 M | $ 25.81 | 0.51 % | $ 16.6 B | ||
|
Aytu BioScience
AYTU
|
6.28 M | $ 2.65 | 0.76 % | $ 16.6 M | ||
|
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B | ||
|
NovaBay Pharmaceuticals
NBY
|
5.82 M | $ 1.5 | 11.94 % | $ 8.73 M | ||
|
Bellerophon Therapeutics
BLPH
|
9.55 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
192 M | $ 4.31 | -2.49 % | $ 826 M | ||
|
AIkido Pharma
AIKI
|
6.18 M | - | 1.93 % | $ 17.4 M | ||
|
Ionis Pharmaceuticals
IONS
|
160 M | $ 69.68 | -1.57 % | $ 11.1 B | ||
|
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
5.39 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
73.9 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M |